Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $98

Benzinga · 1d ago
Stifel analyst Dae Gon Ha maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $92 to $98.